The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, a significant milestone as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS).

The FDA has approved Vykat XR (diazoxide choline) for the treatment of hyperphagia in adults and pediatric patients 4 years ...

The United States Food and Drug Administration (US FDA) has approved VYKAT™ XR, as the first approved treatment for hyperphagia in Prader-Willi syndrome (PWS). IPWSO hopes the US FDA approval is the ...

Soleno Therapeutics (SLNO) stock skyrocketed up over 42% this past week on news that it has achieved a significant milestone with FDA approval ...

Q4 2024 Earnings Call Transcript March 27, 2025 Relmada Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Federal regulators are clearing a first-of-its-kind treatment for symptoms of a rare neurodevelopmental disorder that is ...

Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi ...

Soleno Therapeutics has won US Food and Drug Administration (FDA) approval for diazoxide choline – which will be branded as ...

Soleno Therapeutics stock has surged over 1,500% since September 2023, driven by the progress and today's FDA approval of ...

Diazoxide choline is the first drug indicated for hyperphagia in the rare genetic disorder. Prior to approval, people with ...

Becoming the first treatment for rare genetic disorder Prader-Willi syndrome (PWS), breakthrough therapy drug DCCR (diazoxide choline) gained U.S FDA approval as Vykat XR the evening before March 27, ...